Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 2/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.37 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14136276 | 0.88 | DRD2 (0.44) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14545786 | 0.88 | DRD3 (0.46) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26284685 | 0.88 | SLC6A2 (0.43) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13698216 | 0.84 | DRD2 (0.43) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13698242 | 0.80 | SLC6A2 (0.48) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23993613 | 0.80 | KCNH2 (0.47) | DRD2DRD3ESRRGESRRBESR1 | |
| SCHEMBL2603286 | 0.80 | KCNH2 (0.47) | DRD2DRD3ESRRGESRRBESR1 | |
| SCHEMBL14544201 | 0.78 | RAB9A (0.47) | DRD2DRD3ESRRGESRRBESR1 | |
| SCHEMBL13698223 | 0.78 | DRD2 (0.43) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10057694 | 0.78 | DRD3 (0.54) | DRD2DRD3HTR2BESRRGMCOLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885DRD3 32/4885SLC6A2 276/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885DRD3 32/4885SLC6A2 276/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | DRD2 35/4885DRD3 32/4885SLC6A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.